Study wrapper · #983
Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.
Stefaniak E, Cui B, Yan X, et al. Chemical biology & drug design. 2026.
DOI: 10.1111/cbdd.70332PubMed: 42219795
Editor's note
A laboratory study using cell cultures and biochemical assays, not human data. SS-31 has been studied for its effects on mitochondrial function and protein aggregation relevant to Parkinson's-type pathology. Findings are early-stage and warrant further preclinical work.
Plain-language abstract
In cell and biochemical experiments, SS-31 reduced how alpha-synuclein bound to and clumped on membranes and helped restore mitochondrial function in nerve-like cells.
Related coverage
Weak / none
Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.
Tissue & celln=——2026
Weak / none
Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence.
Journal of radiation researchn=——2026
Supported
Elamipretide: a mitochondria-targeting drug for Barth syndrome.
Trends in pharmacological sciencesn=——2026